⌘K

16:30:02·74d

SECFilingvia Quantisnow

Amendment: SEC Form SCHEDULE 13G/A filed by Compass Therapeutics Inc.

ByQuantisnow·Wall Street's wire, on your screen.

CMPX· Compass Therapeutics Inc.

Health Care

Original source

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Companies

CMPX
Compass Therapeutics Inc.
Health Care

Recent analyst ratings

Apr 28UpdateRaymond James-
Feb 13UpdateCraig Hallum$15.00
Jan 5UpdateWilliam Blair-
Dec 3UpdateCitizens JMP$10.00
Dec 3UpdateCanaccord Genuity$10.00
Dec 3UpdateCantor Fitzgerald-

Related

ANALYST12h
Compass Therapeutics downgraded by Raymond James
SEC1d
Compass Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
PR1d
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
PR4d
Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer
SEC47d
SEC Form S-8 filed by Compass Therapeutics Inc.
SEC54d
SEC Form 10-K filed by Compass Therapeutics Inc.
SEC54d
Compass Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
PR54d
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update